



COVID-19 in Dutch Intensive Care Units;

Patient characteristics and outcomes

compared with pneumonia patients in the ICU from 2017-2019

Version 2022-03-31

This report has been made possible by the effort of all Dutch ICUs from:

Admiraal De Ruyter Ziekenhuis	Martini Ziekenhuis
Albert Schweitzer Ziekenhuis	Meander Medisch Centrum
Alrijne Zorggroep	Medisch Centrum Leeuwarden
Amphia Ziekenhuis	Medisch Spectrum Twente
Amstelland	Máxima MC
Amsterdam UMC - locatie AMC	Nij Smellinghe
Amsterdam UMC - locatie VUmc	Noordwest Ziekenhuisgroep Locatie Alkmaar
Antonius Zorggroep	Noordwest Ziekenhuisgroep Locatie Den Helder
Beatrixziekenhuis Rivas Zorggroep	OLVG
Bernhoven	Ommelander Ziekenhuis Groningen
BovenIJ Ziekenhuis	Radboud UMC
Bravis Ziekenhuis	Reinier de Graaf Gasthuis
Canisius Wilhelmina Ziekenhuis	Rijnstate ziekenhuis
Catharina Ziekenhuis	Rivierenland
Deventer Ziekenhuis	Rode Kruis Ziekenhuis
Diakonessenhuis	Saxenburgh Groep
Dijklander ziekenhuis locatie Hoorn	Slingeland Ziekenhuis
Dijklander ziekenhuis locatie Purmerend	Spaarne Gasthuis locatie Haarlem
Elisabeth Ziekenhuis - TweeSteden	St. Anna Ziekenhuis
Elkerliek Ziekenhuis	St. Antonius Ziekenhuis
Erasmus Medisch Centrum	St. Jans-Gasthuis
Flevoziekenhuis	St. Jansdal
Franciscus Ziekenhuis Locatie Gasthuis	Streekziekenhuis Koningin Beatrix
Franciscus Ziekenhuis Locatie Vlietland	Tergooiziekenhuizen Locatie Blaricum
Gelderse Vallei	Tergooiziekenhuizen Locatie Hilversum
Gelre Ziekenhuis Locatie Apeldoorn	Tjongerschans
Gelre Ziekenhuis Locatie Zutphen	Treant Zorggroep
Haaglanden MC Locatie St Antoniushove	UMC Groningen
Haaglanden MC Locatie Westeinde	UMC Leiden
HagaZiekenhuis	UMC Maastricht
Het Groene Hart Ziekenhuis	UMC Utrecht
IJsselland Ziekenhuis	Van Weel Bethesda Ziekenhuis
Ikazia Ziekenhuis	VieCuri Medisch Centrum
Isala	Wilhelmina Ziekenhuis
Jeroen Bosch Ziekenhuis	Zaans Medisch Centrum
LangeLand Ziekenhuis	Ziekenhuisgroep Twente
Laurentius Ziekenhuis	ZorgSaam Zeeuws-Vlaanderen
Maasstad Ziekenhuis	Zuyderland Locatie Heerlen
Maasziekenhuis Pantein	Zuyderland Locatie Sittard Geleen

Introduction

Despite the increased workload in patient care, all hospitals have put great effort in registering the data concerning COVID-19 patients. By using the online data entry system of the National Intensive Care Evaluation (NICE) foundation a limited amount of data (e.g. admission and discharge date and the age of the patient) on all COVID-19 patients has been recorded. By linking this data to more extensive clinical data, which are being collected regular by the NICE registration, it becomes possible to provide more clarity about the important characteristics and outcomes of COVID-19 patients. Because these extensive clinical data are subsequently supplied in batches from the electronic health record (EHR), these are not yet available for every COVID-19 patient. This means, when reading this report, make sure the results concern an overview of all COVID-19 patients or of COVID-19 patients who are linked to the extensive clinical data.

From February 25, 2021, all individual episodes of patients who have had multiple proven COVID-19 episodes will be included. An episode is defined as a consecutive hospital admission period (in one or more hospitals) in which a patient has tested positive at any time. Once a patient is discharged from hospital and after more than three days is re-admitted to hospital with proven COVID-19, this new hospitalization will be considered as a new COVID-19 episode. This allows one patient to have multiple COVID-19 episodes. This report uses data from all recorded episodes.

This report will be updated frequently in order to include more COVID-19 patients and more clinical data in the analyses. When only a limited amount of episodes can be linked this could lead to bias: a distortion of the results can occur if the linked episodes differ from the non-linked episodes, for instance because the patients of linked episodes have been discharged relatively quickly, or because they died. If more data are available, there will be more certainty about the shown differences between time periods and the associations between patient characteristics and their outcomes.

The data included in this report has been processed by the compilers with the utmost care. The compiler cannot be held liable in any way for information that is nevertheless incomplete or incorrect.

In the table below the total number of admitted COVID-19 episodes, the COVID-19 episodes linked to the clinical data, and SARI patients are shown.

	Number of patients	Number of hospitals
All COVID-19 episodes	17902	72
Linked COVID-19 episodes	16375	72
SARI patients in 2017-2019	19797	80

Comparison COVID-19 with SARI

In this report, the data of the COVID-19 episodes will be compared with a group of patients who was admitted to a Dutch ICU with severe pneumonia between the period of 1 January 2017 till 31 December 2019. This group is being called Severe Acute Respiratory Infection (SARI). In this report, SARIs will be defined based on the following (APACHE IV) reasons of admission: Pulmonary sepsis; Viral pneumonia; Aspiration pneumonia; Bacterial pneumonia; Fungal pneumonia; Parasitic pneumonia (i.e. Pneumocystis pneumonia); Other pneumonia.


ICU length of stay

The table below shows the mean ICU length of stay of all COVID-19 episodes and admitted SARI patients, of the COVID-19 episodes of which the patients are still in the ICU, and of COVID-19 episodes and SARI patients who have been discharged recently split up into different discharge destinations. If a COVID-19 patient has been transferred to another ICU during the episode, all ICU length of stays will be added up together. The length of stay is calculated in days ((discharge date - admission date)+1).

	Number of COVID-19 episodes	Mean length of stay (SD)	Number of SARI patients	Mean length of stay (SD)
Patients who are currently being treated in the ICU *	129	12.4 (18.1)	0	-
Discharged to nursing ward in same or different hospital	12759	16.0 (18.9)	14103	5.9 (9.6)
Other discharge destination	648	18.2 (24.5)	2235	7.1 (11.1)
Died in the ICU	4366	18.1 (17.3)	3459	7.1 (10.5)
TOTAL	17902	16.6 (18.8)	19797	6.2 (10.0)

**N.B. For the COVID-19 episodes of which the patient is currently admitted, it concerns the ICU length of stay up till the moment that this report was generated and not the final total length of stay.*

The figure and table below show the age distribution of all COVID-19 episodes, the linked COVID-19 episodes and the SARI patients.




	Mean age (SD)
All COVID-19 episodes	61.9 (12.5)
Linked COVID-19 episodes	61.9 (12.3)
SARI patients in 2017-2019	66.3 (14.2)


Patient characteristics

In the remainder of this report, the extensive data from the NICE registration will be used. Therefore, from here on, only the linked COVID-19 episodes will be included. This group will continuously be compared with the SARI patients who have been admitted to the ICU in the previous three years (2017-2019).

In the figure below the distribution of men and women in the linked COVID-19 episodes and the SARI patients is shown.



In the graph below, the BMI-distribution of the linked COVID-19 episodes and the SARI patients is shown.




	Mean BMI (SD)
Linked COVID-19 episodes	29.6 (5.6)
SARI patients in 2017-2019	26.2 (6.0)

The table below shows for several different comorbidities (secondary diagnoses) the number and percentage of episodes of which the patient had the concerning comorbidity. Additionally, this table shows the number and percentage of episodes of which the patient were mechanically ventilated at ICU admission, and that were mechanically ventilated within the first 24 hours of ICU admission.

	COVID-19 episodes N(%)	SARI patients N(%)
COPD/Respiratory insufficiency	2012 (12.3)	7532 (38)
Renal failure	682 (4.2)	1722 (8.7)
Cirrhosis	74 (0.5)	238 (1.2)
Cardiovascular insufficiency	252 (1.5)	764 (3.9)
Malignancy/Haematological insufficiency	427 (2.6)	1960 (9.9)
Immunological insufficiency	1560 (9.5)	3808 (19.2)
Diabetes	3633 (22.2)	3997 (20.2)
Mechanically ventilated at ICU admission	4702 (28.7)	7923 (40.0)
Mechanically ventilated within the 1st 24 hours	10045 (61.3)	11124 (56.2)

In the graph below, the percentage of COVID-19 episodes of which the patient had no, one or more than one comorbidities are given for different age groups.



**Note since the report of 2020-12-10 diabetes is also counted as a comorbidity, as a result of this the percentage of episodes of which patient had one or more comorbidities may have increased compared to previous reports.*

Patient outcomes and determinants

In the table below important characteristics belonging to COVID-19 episodes of which the patient died are compared with COVID-19 episodes of which the patient survived.

N.B. This analysis excludes the episodes of which the patient is still admitted at the Intensive Care. However, the number of these episodes are being shown in the last column of the table. The listed percentages should be read horizontally.

Per patient characteristic, the number and percentage of episodes of which the patient deceased and survived has been displayed. The column containing the P-value shows whether the differences between the episodes of deceased and survived patients are statistically significant. A P-value smaller than 0.05 shows that the presented differences are statistically significant (cannot be explained based on coincidence). A P-value of 0.05 or bigger means that the discovered differences are probably a coincidence.

Finally, the association between the patient characteristic and mortality is shown with Odds Ratio's (OR). An OR shows approximately how much the risk of dying is increased in relation to the comparison category, also known as the reference population. Regarding age: due to the small numbers, the seven youngest age categories have been combined into one reference population. Therefore, in the remaining age categories the OR indicate how much more the risk of dying is increased in comparison to this reference population. The 95%-confidence interval (CI) of the OR is displayed in the second last column and indicates whether the association found between the patient characteristics and mortality is statistically significant (confidence interval does NOT include 1) or not significant (confidence interval DOES include 1).


	COVID-19 survivors N (%)	COVID-19 deceased N (%)	P-value	Odds ratio (95% CI)	COVID-19 still in hospital N
All episodes	11348 (71.3)	4561 (28.7)			466
Age groups			<0.001		
0-17	8 (88.9)	1 (11.1)		reference	1
18-24	101 (97.1)	3 (2.9)		reference	6
25-29	156 (94)	10 (6)		reference	6
30-34	270 (96.1)	11 (3.9)		reference	14
35-39	357 (93.9)	23 (6.1)		reference	10
40-45	450 (91.6)	41 (8.4)		reference	17
45-50	827 (91.3)	79 (8.7)		reference	19
50-55	1293 (86.8)	196 (13.2)		1.95 (1.57-2.43)	60
55-60	1718 (83.8)	331 (16.2)		2.48 (2.04-3.02)	59
60-65	1857 (76)	585 (24)		4.06 (3.38-4.87)	65
65-70	1780 (65.9)	920 (34.1)		6.66 (5.59-7.94)	65
70-75	1571 (56.3)	1219 (43.7)		10 (8.4-11.89)	83
75-80	766 (47.5)	847 (52.5)		14.24 (11.84-17.13)	83
80-85	165 (39.3)	255 (60.7)		19.91 (15.49-25.58)	83
>85	21 (35)	39 (65)		23.92 (13.76-41.59)	83
Gender			<0.001		
Men	7552 (69.4)	3334 (30.6)		reference	313
Woman	3796 (75.6)	1227 (24.4)		0.73 (0.68-0.79)	153

	COVID-19 survivors N (%)	COVID-19 deceased N (%)	P-value	Odds ratio (95% CI)	COVID-19 still in hospital N
BMI groups					
<18.5	50 (64.9)	27 (35.1)	<0.001	1.06 (0.66-1.71)	5
18.5-25	2004 (66.2)	1025 (33.8)		reference	112
25-30	4396 (70.3)	1853 (29.7)		0.83 (0.76-0.91)	163
30-35	2857 (74.4)	981 (25.6)		0.68 (0.61-0.75)	112
35-40	1175 (75.1)	389 (24.9)		0.65 (0.57-0.75)	42
>40	626 (78.6)	170 (21.4)		0.53 (0.44-0.64)	19
Comorbidities					
COPD & respiratory insufficiency No	10169 (72.8)	3793 (27.2)	<0.001	reference	401
COPD & respiratory insufficiency Yes	1179 (60.6)	768 (39.4)		1.75 (1.58-1.93)	65
Renal failure No	11072 (72.6)	4183 (27.4)	<0.001	reference	438
Renal failure Yes	276 (42.2)	378 (57.8)		3.63 (3.09-4.25)	28
Cardiovascular insufficiency No	11233 (71.7)	4437 (28.3)	<0.001	reference	453
Cardiovascular insufficiency Yes	115 (48.1)	124 (51.9)		2.73 (2.11-3.53)	13
Malignancy No	11156 (72)	4340 (28)	<0.001	reference	452
Malignancy Yes	192 (46.5)	221 (53.5)		2.96 (2.43-3.6)	14
Immunological insufficiency No	10514 (72.9)	3899 (27.1)	<0.001	reference	402
Immunological insufficiency Yes	834 (55.7)	662 (44.3)		2.14 (1.92-2.39)	64
Number of comorbidities					
None	7363 (77.3)	2162 (22.7)	<0.001	reference	262
1	3174 (66.9)	1567 (33.1)		1.67 (1.54-1.8)	131
>1	811 (49.4)	832 (50.6)		3.4 (3.05-3.8)	73
Diagnoses at ICU-admission					
Cardiopulmonary resuscitation No	11276 (71.9)	4416 (28.1)	<0.001	reference	459
Cardiopulmonary resuscitation Yes	72 (33.2)	145 (66.8)		5.14 (3.87-6.84)	7
Mechanical ventilation at admission No	8377 (73.9)	2954 (26.1)	<0.001	reference	342
Mechanical ventilation at admission Yes	2971 (64.9)	1607 (35.1)		1.53 (1.42-1.65)	124
Gastrointestinal bleeding No	11323 (71.4)	4545 (28.6)	0.147	reference	464
Gastrointestinal bleeding Yes	25 (61)	16 (39)		1.59 (0.85-2.99)	2
Diabetes No	9061 (73.2)	3315 (26.8)	<0.001	reference	366
Diabetes Yes	2287 (64.7)	1246 (35.3)		1.49 (1.38-1.61)	100
Diagnoses in 1st 24 hours of ICU-admission					
Acute renal failure No	10865 (73.2)	3969 (26.8)	<0.001	reference	427
Acute renal failure Yes	483 (44.9)	592 (55.1)		3.36 (2.96-3.8)	39
Mechanical ventilation within the 1st 24 hours No	4754 (77.6)	1369 (22.4)	<0.001	reference	207
Mechanical ventilation within the 1st 24 hours Yes	6594 (67.4)	3192 (32.6)		1.68 (1.56-1.81)	259
Confirmed infection No	2309 (71.5)	920 (28.5)	0.82	reference	125
Confirmed infection Yes	9039 (71.3)	3641 (28.7)		1.01 (0.93-1.1)	341
Vasoactive medication No	6081 (77.1)	1803 (22.9)	<0.001	reference	241
Vasoactive medication Yes	5267 (65.6)	2758 (34.4)		1.77 (1.65-1.89)	225


Kaplan Meier survival curve

In the figure below, one can see a first estimate of the percentage of COVID-19 episodes (the vertical axis) of which patients survived the hospitalisation, including a period in ICU, since the day of ICU admission until a certain moment in time (the horizontal axis). In the first figure a distinction has been made between all COVID-19 episodes (black line), the linked COVID-19 episodes (red line) and the SARI patients from the years 2017-2019 (blue line). The second figure shows the linked COVID-19 episodes of which the patient has (red line) or has not (blue line) been mechanically ventilated at the first day of admission.

These estimations have to be interpreted with care, because the episodes of which the patient is currently being treated have been included in these analyses too and consequently their outcome is not yet known. Therefore, based on this figure we cannot conclude that COVID-19 patients have a better prognosis compared to the SARIs. The current group of COVID-19 episodes and the previous SARI patients possibly differ regarding important clinical characteristics such as age and secondary diseases such as diabetes or COPD. Further research could prove whether the survival chance differs between the COVID-19 and SARI population.



	0	10	20	30	40	50	60
SARI	19797	9841	3905	1959	1142	682	429
COVID-19	17902	14020	8191	4944	3192	2176	1472



Aantal episoden at risk

Mech. ventilated in first 24 hrs	10045	8675	5579	3429	2203	1466	953
Not mech. ventilated in first 24 hrs	6330	4394	2114	1226	803	576	419

Groups of COVID-19 patients admitted to the ICU and their survival chances

To provide more insight into the chance of survival of COVID-19 patients at the time of ICU admission, a table with survival chances of different COVID-19 patients groups has been made based on the data of 13,389 COVID-19 patients admitted to the ICU between February 27, 2020 and November 23, 2021. In the analyses, the in-hospital mortality/survival was used as outcome measure. The MDS data items known at the time of ICU admission were used to identify distinguishing groups: admission type, age, gender, readmission, referring specialty, BMI, duration of treatment before ICU admission, number of chronic comorbidities (being one of the following comorbidities defined in the NICE Data Dictionary: (1) immunologic insufficiency or AIDS; (2) chronic renal failure or chronic dialysis; (3) respiratory failure or COPD; (4) neoplasm or haematological malignancy; (5) cardiovascular insufficiency ; (6) liver cirrhosis; (7) diabetes). The groups as shown in the table were generated using a regression tree analysis. For a more detailed explanation, see

<https://stichting-nice.nl/download/file?link=HulpmiddelCOVIDpatie776ntenvoorICopname>.

Group	Age	Number of comorbidities	Survival chance
1	≤58	≤1	90.0%
2	≥59 en ≤65	≤1	78.8%
4	≥66 en ≤70		66.4%
3	≤65	≥2	62.5%
5	≥71 en ≤77	0	60.3%
6	≥71 en ≤77	≥1	48.6%
7	≥78		41.2%

Variations over time


COVID-19 is a new clinical condition for which new knowledge is continuously being obtained, new treatment methods are used and as a result the prognoses / outcomes of the patients may change. To provide insight into these changes, the section below of the report will break down some important patient characteristics and outcomes into two-month periods of the COVID-19 epidemic.

The table below shows the number of COVID-19 episodes per two months.

	Number of episodes	Number of episodes of which the patient is deceased (%) *	Number of episodes linked to clinical data (%)
March-April 2020	2670	820 (30.7)	2605 (97.6)
May-June 2020	199	37 (18.6)	191 (96.0)
July-August 2020	125	30 (24.0)	120 (96.0)
Sept-Oct 2020	1422	469 (33.0)	1373 (96.6)
Nov-Dec 2020	2202	719 (32.7)	2091 (95)
Jan-Feb 2021	2026	564 (27.8)	1979 (97.7)
March-April 2021	2962	748 (25.3)	2914 (98.4)
May-June 2021	1113	225 (20.2)	1077 (96.8)
July-August 2021	722	142 (19.7)	687 (95.2)
Sept-Oct 2021	735	208 (28.3)	688 (93.6)
Nov-Dec 2021	2385	682 (28.6)	2110 (88.5)
Jan-Feb 2022	875	216 (24.7)	494 (56.5)
March-April 2022	453	62 (13.7)	38 (8.4)


** Note a large proportion of patients of the episodes from the more recent periods are still hospitalized of which a part may still die, so the numbers can still rise (considerably).*

The figure and table below shows the age distribution of the patients from all COVID-19 episodes over different time periods.




	Mean age (SD)	Median Age (IQR)
March-April 2020	63.4 (11.2)	65 (57-72)
May-June 2020	60.9 (13.1)	61 (53-70)
July-August 2020	60.5 (13.4)	64 (51-70)
Sept-Oct 2020	64.2 (11.9)	66 (57-73)
Nov-Dec 2020	64.7 (11.1)	66 (58-73)
Jan-Feb 2021	62.8 (11.5)	64 (57-71)
March-April 2021	61.8 (11.7)	64 (55-71)
May-June 2021	59.1 (12.0)	59 (52-69)
July-August 2021	55.1 (14.6)	56 (46-66)
Sept-Oct 2021	58.9 (14.5)	61 (50-70)
Nov-Dec 2021	60.6 (13.2)	63 (53-71)
Jan-Feb 2022	60.3 (14.1)	63 (53-70)
March-April 2022	63.2 (15.6)	67 (57-74)

The figure and table below shows the BMI distribution of the patients of all COVID-19 episodes over different time periods.



	Mean BMI (SD)	Median BMI (IQR)
March-April 2020	28.7 (4.9)	27.8 (25.3-31.1)
May-June 2020	29.5 (5.7)	28.4 (25.5-32.2)
July-August 2020	29.3 (6.6)	27.9 (24.7-32.8)
Sept-Oct 2020	29.3 (5.3)	28.7 (25.6-32.0)
Nov-Dec 2020	29.4 (5.3)	28.4 (25.7-32.3)
Jan-Feb 2021	29.7 (5.6)	28.7 (25.8-32.8)
March-April 2021	30.1 (5.9)	29.1 (26.0-32.9)
May-June 2021	30.3 (6.0)	29.4 (26.1-33.5)
July-August 2021	30.2 (6.3)	29.2 (25.8-33.6)
Sept-Oct 2021	30.2 (6.3)	29.3 (25.8-33.3)
Nov-Dec 2021	29.6 (5.7)	28.7 (25.8-32.6)
Jan-Feb 2022	29.1 (6.5)	28.1 (24.8-32.4)
March-April 2022	27.8 (6.2)	26.5 (24.7-31.1)

In the graph below, the percentage episodes of which the patients had no, one or more than one comorbidities are given for different periods.



**Note since the report of 2020-12-10 diabetes is also counted as a comorbidity, as a result of this the percentage episodes of which patients had no, one or more than one comorbidities may have increased compared to previous reports.*

The table below shows per two months period the mean ICU length of stay of all COVID-19 episodes, of the COVID-19 episodes of which the patient is still in the ICU, and of COVID-19 episodes of which the patient has been discharged recently split up into different discharge destinations. If a patient has been transferred to another ICU during an episode, all ICU length of stays will be added up together. The length of stay is calculated in days ((discharge date - admission date)+1).

Note that the most recent period still yields many uncertain results because a large part of this population is still included, so the averages shown will most likely increase.


	Number of episodes	Mean length of ICU stay (SD)
Period March-April 2020		
Patients who are currently being treated in the ICU *	0	-
Discharged to nursing ward in same or different hospital	1818	22 (17.4)
Other discharge destination	103	26.6 (33.1)
Died in the ICU	749	15.9 (18.4)
TOTAL	2670	20.4 (18.8)
Period May-June 2020		
Patients who are currently being treated in the ICU *	0	-
Discharged to nursing ward in same or different hospital	159	15.7 (14.9)
Other discharge destination	10	19.8 (32.4)
Died in the ICU	30	13.4 (10.4)
TOTAL	199	15.5 (15.5)
Period July-August 2020		
Patients who are currently being treated in the ICU *	0	-
Discharged to nursing ward in same or different hospital	96	13.5 (15.8)
Other discharge destination	7	22.7 (21.9)
Died in the ICU	22	16.8 (16.6)
TOTAL	125	14.6 (16.3)
Period Sept-Oct 2020		
Patients who are currently being treated in the ICU *	0	-
Discharged to nursing ward in same or different hospital	982	15.7 (17.6)
Other discharge destination	34	16.6 (19.2)
Died in the ICU	406	19.6 (14)
TOTAL	1422	16.8 (16.8)
Period Nov-Dec 2020		
Patients who are currently being treated in the ICU *	0	-
Discharged to nursing ward in same or different hospital	1515	16.7 (18.1)
Other discharge destination	61	16.7 (17.9)
Died in the ICU	626	18.1 (14.3)
TOTAL	2202	17.1 (17.1)
Period Jan-Feb 2021		
Patients who are currently being treated in the ICU *	0	-
Discharged to nursing ward in same or different hospital	1490	17 (25.8)
Other discharge destination	37	18.9 (21.2)
Died in the ICU	499	19.3 (22.1)
TOTAL	2026	17.6 (24.9)
Period March-April 2021		
Patients who are currently being treated in the ICU *	0	-
Discharged to nursing ward in same or different hospital	2215	15.1 (16.1)
Other discharge destination	77	22.8 (29.7)
Died in the ICU	670	19.6 (14.3)
TOTAL	2962	16.3 (16.3)

	Number of episodes	Mean length of ICU stay (SD)
Period May-June 2021		
Patients who are currently being treated in the ICU *	0	-
Discharged to nursing ward in same or different hospital	873	14.9 (17.0)
Other discharge destination	40	24.1 (26.8)
Died in the ICU	200	19.6 (14.8)
TOTAL	1113	16.1 (17.2)
Period July-August 2021		
Patients who are currently being treated in the ICU *	0	-
Discharged to nursing ward in same or different hospital	557	14.2 (16.4)
Other discharge destination	36	23.1 (32.7)
Died in the ICU	129	20.4 (14.6)
TOTAL	722	15.7 (17.4)
Period Sept-Oct 2021		
Patients who are currently being treated in the ICU *	1	71 (-)
Discharged to nursing ward in same or different hospital	531	14.2 (14.8)
Other discharge destination	24	9.3 (10.9)
Died in the ICU	179	20.3 (13.8)
TOTAL	735	15.6 (14.9)
Period Nov-Dec 2021		
Patients who are currently being treated in the ICU *	7	15.1 (20.5)
Discharged to nursing ward in same or different hospital	1645	13.9 (13.8)
Other discharge destination	133	15.2 (19.1)
Died in the ICU	600	16.7 (13.0)
TOTAL	2385	14.6 (17.1)
Period Jan-Feb 2022		
Patients who are currently being treated in the ICU *	20	18.6 (16.9)
Discharged to nursing ward in same or different hospital	613	9.9 (11.2)
Other discharge destination	48	9.4 (12.0)
Died in the ICU	194	15.2 (12.6)
TOTAL	875	11.2 (11.8)
Period March-April 2022		
Patients who are currently being treated in the ICU *	100	3.7 (2.9)
Discharged to nursing ward in same or different hospital	257	4.4 (3.7)
Other discharge destination	37	3.0 (2.2)
Died in the ICU	59	5.7 (5.1)
TOTAL	453	4.4 (3.9)

**N.B. For the COVID-19 episodes of which the patient is currently admitted, it concerns the ICU length of stay up till the moment that this report was generated and not the final total length of stay.*

The figure below shows an initial estimate per period of the percentage of COVID-19 episodes (the vertical axis) of which the patient survived hospitalization, including admission to the ICU, until a certain moment (the horizontal axis) after the start of the ICU admission.

These estimates must be interpreted with caution, because the patients who are currently being treated have also been included and the outcome of them is therefore not yet known.



The table below shows the (univariate) Odds Ratio (OR) of the two monthly periods. An OR shows approximately how much the risk of dying is increased in relation to the reference group, i.e. the months March and April. The 95% confidence interval of the OR indicates whether the relationship found between the period and mortality is significant (confidence interval includes 1 NOT) or not significant (confidence interval includes 1 DO). Note this is a univariate analysis meaning that no adjustment has been made for differences in patient characteristics over time. It is also important to realize that a large proportion of patients from the episodes of the more recent periods are still hospitalized. These are included in the calculations as survivors, while a part may still die, so that the odds ratio can still rise (considerably).

	Odds ratio (CI)
March-April 2020	Reference
May-June 2020	0.52 (0.36-0.74)
July-August 2020	0.71 (0.47-1.08)
Sept-Oct 2020	1.11 (0.97-1.27)
Nov-Dec 2020	1.09 (0.97-1.23)
Jan-Feb 2021	0.87 (0.77-0.99)
March-April 2021	0.76 (0.68-0.86)
May-June 2021	0.57 (0.48-0.68)
July-August 2021	0.55 (0.45-0.68)
Sept-Oct 2021	0.89 (0.74-1.07)
Nov-Dec 2021	0.90 (0.80-1.02)
Jan-Feb 2022	0.74 (0.62-0.88)
March-April 2022	0.36 (0.27-0.47)

COVID-19 and SOFA

For this report, the data of the COVID-19 episodes are also linked to the information about organ failure that is supplied to NICE in the Sequential Organ Failure Assessment (SOFA) registration module. About half of the ICUs in the Netherlands register this SOFA data. In the table below, in addition to the number of COVID-19 episodes that could be linked to the clinical information, the number of COVID-19 episodes that could be linked to the SOFA data is shown.

	Number of COVID-19 episodes
Linked to clinical (MDS) data	16375
Linked to organ failure (SOFA) data	8685

The table below shows in how many COVID-19 episodes and how many SARI patients received treatment with different types of organ support. For the patients receiving the particular organ support it is also shown how many calendar days they received this support on average during the ICU admission. Finally, the average number of calendar days on which the measured platelet was <50 is shown.

	COVID-19 episodes N (%)	Mean number of days (SE)	SARI patients N (%)	Mean number of days (SE)
Basic respiratory support	6346 (73.1)	10.5 (11.6)	5114 (59.1)	6.5 (8.5)
Advanced respiratory support	42 (0.5)	3.8 (7.9)	169 (2)	3.7 (6.7)
Artificial liver support	1 (0)	1 (NA)	0 (0)	-
Cardiac support using cardiac assist device	29 (0.3)	8.2 (14.8)	57 (0.7)	10.4 (14.3)
Renal support using renal replacement therapy	664 (7.6)	10.1 (10.4)	565 (6.5)	8.1 (9.4)
Measured platelets value <50	383 (4.4)	2.6 (3.6)	512 (5.9)	4.8 (5.6)